Curing the Disobedient Patient: Medication Adherence Programs as Pharmaceutical Marketing Tools

Wolston M. , “An MS Patient Loses Trust When She Finds Out Her Doctor Is Paid by Drug Companies,” Health Affairs 30, no. 12(2011): 2449–2452.

See, e.g., Conrad P. , “The Meaning of Medications: Another Look at Compliance,” Social Science and Medicine 20, no. 1(1985).

Holm S. , “What Is Wrong with Compliance?” Journal of Medical Ethics 19, no. 2(1993): 108–110.

“Understanding and Improving Adherence for Specialty Products,” IMS Health, available at <http://www.imshealth.com/deployedfiles/ims/Global/Content/Solutions/Healthcare%20Analytics%20and%20Services/Specialty%20Analytics/Understanding_Improving_Adherence_Specialty_Products.pdf>(last visited November 19, 2014).

Rundall T. , “As Good as It Gets? Chronic Care Management in Nine Leading U.S. Physician Organizations,” BMJ 325 (2002): 958–961.

Anderson G. Knickman J. , “Changing the Chronic Care System to Meet People's Needs,” Health Affairs 20, no. 6(2001): 146–160.

“Adherence to Long-Term Therapies: Evidence for Action,” World Health Organization, 2003, available at <http://apps.who.int/medicinedocs/en/d/Js4883e/>(last visited November 19, 2014).

Ho P. M. Magid D. J. Masoudi F. A. McClure D. L. Rumsfeld J. S. , “Adherence to Cardioprotective Medications and Mortality among Patients with Diabetes and Ischemic Heart Disease,” BMC Cardiovascular Disorders 6 (2006): 48.

Marcum Z. A. Sevick M. Handler S. M. , “Medication Nonadherence: A Diagnosable and Treatable Medical Condition,” JAMA 309, no. 20(2013): 2105–2106.

New England Health Institute, “Thinking Outside the Pillbox: A System-Wide Approach to Improving Patient Medication Adherence for Chronic Disease,” August 2009.

Capgemini Consulting & HealthPrize Technologies, “Annual Pharmaceutical Revenue Loss Due to Medication Non-Adherence,” available at <https://www.adherence564.com/>(last visited November 19, 2014).

Baum S. , “Pharma Patient Adherence Budgets Have Increased 281 Percent in Four Years,” MedCity News, October 12, 2012, available at <http://medcitynews.com/2012/10/pharmapatient-adherence-budgets-have-increased-281-percent-in-four-years/#ixzz2t7sGEyYr>(last visited November 19, 2014).

McKesson Medication Adherence Programs Achieve New Levels of Patient Adoption and Loyalty, Press Release, June 3, 2010, available at <http://www.mckesson.com/about-mckesson/newsroom/press-releases/2010/mckesson-medication-adherence-programs-achieve-new-levels-of-patient-adoption-and-loyalty/>(last visited November 19, 2014).

Arnold M. , “Thinking Past the Pill,” Medical Marketing & Media, October 2010, available at <http://www.mmm-online.com/patient-marketing-report-thinking-past-the-pill/article/180045/>(last visited November 19, 2014).

Rose D. , “The Reason Why: Smart Packaging Can Improve Habits and Transform Healthcare,” Healthspottr, Issue 5, November 19, 2009.

Id.

Pollack A. , “Take Your Pills, All Your Pills,” New York Times, March 11, 2006.

Frost & Sullivan Whitepaper, Patient Nonadherence: Tools for Combating Persistence and Compliance Issues, available at <http://www.frost.com/prod/servlet/cpo/115071625.pdf%C3%BD>(last visited November 19, 2014).

Harris Interactive, “Oil, Pharmaceutical, Health Insurance, Tobacco, Banking and Utilities Top the List of Industries That People Would Like to See More Regulated,” December 18, 2012, available at <http://www.harrisinteractive.com/News-Room/HarrisPolls/tabid/447/mid/1508/articleId/1131/ctl/ReadCustom%20Default/Default.aspx>(last visited November 19, 2014).

Bertha B. , “The Artful Science of Medication Adherence,” PM360, June 2010.

Id.

Gallup, “Honesty/Ethics in Professions,” December 2013, available at <http://www.gallup.com/poll/1654/honesty-ethics-professions.aspx>(last visited November 19, 2014).

Allen J. Bell C. , “Nurses: They're Not Just in Hospitals Anymore,” PharmaPhorum, November 27, 2013, available at <http://www.pharmaphorum.com/articles/nurses-theyre-not-just-in-hospitals-anymore>(last visited November 19, 2014).

See Pollack , supra note 15.

UBC, “Nursing and Adherence,” available at <http://www.ubc.com/services/loyalty/nursing-adherence>(last visited November 19, 2014).

Ad Age Insights White Paper, Pharmaceutical Marketing, October 17, 2011, available at <http://adage.com/images/bin/pdf/WPpharmmarketing_revise.pdf>(last visited November 19, 2014).

See Gallup Honesty/Ethics in Professions Poll, supra note 20.

See Ad Age Insights White Paper, supra note 24.

McKesson Patient Relationship Solutions, “Sponsored Clinical Services,” available at <http://mprsannounce.mckesson.com/MPRS/microsite/sponsored_clinical_services.htm>(last visited November 19, 2014).

McKesson Patient Relationship Solutions, “Pharmacy Intervention Program,” available at <http://mprsannounce.mckesson.com/MPRS/microsite/pharmacy_intervention_program.htm>(last visited November 19, 2014).

Bertha B. , “The Artful Science of Medication Adherence,” PM360, June 2010.

McKesson Patient Relationship Solutions, available at <http://mprsannounce.mckesson.com/MPRS/microsite/welcome.htm>(last visited November 19, 2014)

McKesson Patient Relationship Solutions, “The Future of Medication Adherence,” March 2012.

Snow B. , “Magnifying the Authentic Voice of the Patient, DTC Perspectives,” March 2010, available at <http://www.dtcperspectives.com/wp-content/uploads/2011/02/PatientAmbassadors.pdf>(last visited November 19, 2014).

Snow B. , “Make Contact,” Pharmaceutical Marketing Europe, January/February 2010.

Snow B. , “Magnifying the Authentic Voice of the Patient,” DTC Perspectives, March 2010, available at <http://www.dtcperspectives.com/wp-content/uploads/2011/02/PatientAmbassa-dors.pdf>(last visited November 19, 2014).

Snow & Associates job posting for Advocacy and Recruitment Associate, available at <http://intranet.snow-companies.com/share/jobposting/0000873>(last visited November 19, 2014).

Snow & Associates, When Executed Effectively and Consistent with FDA Guidelines, Patient Testimonials Continue to Be a Powerful Vehicle for Communicating with Health Consumers Snow: Best Practices 2010, available at <http://snow-companies.com/page/sites/default/files/(5)%20Snow_Regulatory_Position_03_10.pdf>(last visited November 19, 2014).

Lamkin M. , “Health Care Reform, Wellness Programs & the Erosion of Informed Consent,” Kentucky Law Journal 101 (2013): 435.

Marcum Z. A. Sevick M. Handler S. M. , “Medication Nonadherence: A Diagnosable and Treatable Medical Condition,” JAMA 309, no. 20(2013): 2105–2106.

Boston Consulting Group, The Hidden Epidemic: Finding a Cure for Unfilled Prescriptions and Missed Doses (2003), available at <http://www.bcg.com/documents/file14265.pdf>(last visited November 19, 2014).

Ioannidis J. P. A. , “Contradicted and Initially Stronger Effects in Highly Cited Clinical Research,” JAMA 294, no. 2(2005): 218–228, at 224.

Giugliano D. Esposito K. , “Clinical Inertia as a Clinical Safeguard,” JAMA 305 (2011): 1591–1592.

Garfinkel D. Mangin D. , “Feasibility Study of a Systematic Approach for Discontinuation of Multiple Medications in Older Adults: Addressing Polypharmacy,” Archives of Internal Medicine 170, no. 18(2010): 1648–1654.

See Ioannidis , supra note 39, at 223.

Id.

Harris G. , “Diabetes Drug Maker Hid Test Data, Files Indicate,” New York Times, July 13, 2010, at A1.

Nissen S. E. Wolski K. , “Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes,” New England Journal of Medicine 356, no. 24(2007): 2457–2471.

Harris G. , “F.D.A. to Restrict Avandia, Citing Heart Risk,” New York Times, September 23, 2010, at A1.

Moncrie J. Cohen D. Mason J. P. , “The Subjective Experience of Taking Antipsychotic Medication: A Content Analysis of Internet Data,” Acta Psychiatrica Scandinavica 120, no. 2(2009): 102–111.

Priebe S. Burton A. , “Financial Incentives to Improve Adherence to Anti-psychotic Maintenance Medication in Non-adherent Patients: A Cluster Randomised Controlled Trial (FIAT),” BMC Psychiatry 9 (2009), available at <http://www.biomedcentral.com/1471–244X/9/61>(last visited November 19, 2014).

See <http://relationalagents.com/publications/CHI08-mentalhealth.pdf>(last visited November 19, 2014). Bickmore T. Puskar K. , “Maintaining Reality: Relational Agents for Antipsychotic Medication Adherence,” Interacting with Computers 22, no. 4(2010): 276–288.

Whitaker R. , Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America, Broadway Books, 2011.

Lieberman J. A. , “Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia,” New England Journal of Medicine 353, no. 12(2005): 1209–1223.

Khan H. Thomas P. , “Drug Giant AstraZeneca to Pay $520 Million to Settle Fraud Case,” ABC News, April 27, 2010, available at <http://abcnews.go.com/Politics/Health/astrazenecapay-520-million-illegally-marketing-seroquel-schizophrenia/story?id=10488647>(last visited November 19, 2014).

Copaxone Prescribing Information, available at <http://copaxone.com/pdfs/PrescribingInformation.aspx>(last visited November 19, 2014).

La Mantia L. Munari L. M. Lovati R. , “Glatiramer Acetate for Multiple Sclerosis (Review),” The Cochrane Library 5 (2010), available at <http://www.bibliotecacochrane.com/pdf/CD004678.pdf>(last visited November 19, 2014).

Elliott C. , White Coat, Black Hat: Adventures on the Dark Side of Medicine (Boston: Beacon Press, 2010.).

Frost & Sullivan, The Evolution of Patient Adherence Programs: Moving from Mass Market Relationships to a Personal Approach, available at <https://www.frost.com/prod/servlet/cpo/115071626.pdf>(last visited November 19, 2014).

McKesson Patient Relationship Solutions, The Future of Medication Adherence, March 2012.

Grant B. , “Merck Produced Fake Journal,” The Scientist, April 30, 2009, available at <http://www.the-scientist.com/?articles.view/articleNo/27376/title/Merck-published-fake-journal/>(last visited November 19, 2014).

See Pollack , supra note 15.